Ad. Min et al., Efficacy of high-dose interferon in combination with ribavirin in patientswith chronic hepatitis C resistant to interferon alone, AM J GASTRO, 96(4), 2001, pp. 1143-1149
OBJECTIVE: Interferon combined with ribavirin has efficacy in the treatment
of patients with chronic hepatitis C virus (HCV) infection. However, its u
tility in patients who have not responded to prior interferon therapy is no
t clear. Furthermore, the effect of using an increased dose of interferon i
n combination with ribavirin in patients with chronic hepatitis C resistant
to conventional doses of interferon is not known. The aim of our study was
to evaluate the effect of high-dose interferon in combination with ribavir
in on the efficacy of treating patients with chronic hepatitis C resistant
to interferon monotherapy in a large multicenter trial.
METHODS: We randomized 154 patients with chronic hepatitis C who failed to
achieve a sustained response with prior interferon therapy to receive eithe
r 3 or 5 MU of interferon alpha -2b and ribavirin (1000-1200 mg/day) for 12
months. There were 119 patients who had not responded and 35 who initially
responded but relapsed after prior interferon monotherapy. Serum HCV RNA l
evels were measured at entry, 6, and 12 months of treatment and at the end
of a 6-month follow-up period.
RESULTS: The mean age of the subjects was 47 yr (range 28-68 yr), and 110 (
71.4%) were men. One hundred thirty-two patients (86%) had HCV genotype 1,
whereas 21(14%) had cirrhosis. Eighty-one subjects (53%) were randomized to
receive 3 MU of interferon alpha -2b. Fifteen of 35 relapse subjects (43%)
and 12 of 119 prior nonresponder entrants (10%) achieved a sustained virol
ogical response to the 12-month course of treatment. Overall, 11 of 81 pati
ents (14%) receiving 3 MU, and 16 of 73 patients (22%) receiving 5 MU of in
terferon maintained an undetectable HCV RNA level after cessation of therap
y. The difference in sustained response rates between the two interferon do
sage groups did not reach statistical significance (p = 0.09). However, amo
ng the nonresponder patients alone, there was an increased sustained respon
se in the high-dose interferon group compared with the standard interferon
dose group (15.5% vs 4.9%, p = 0.055). Twenty-six patients discontinued the
rapy before 6 months, including 10 patients (12.3%) in the 3-MU and 16 pati
ents (21.9%) in the 5-MU groups (p = 0.17).
CONCLUSIONS: Sustained virological response to combined interferon alpha -2
b and ribavirin was significantly higher in relapse patients than those who
did not respond to prior interferon monotherapy. Although, when all treate
d patients were analyzed, there was no significant difference in sustained
response between subjects receiving 3 and 5 MU of interferon, among the pri
or nonresponder patients, treatment with 5 MU of interferon with ribavirin
resulted in a slightly increased response compared with treatment with the
standard interferon dosage. The tolerability of the treatment regimens was
comparable. (Am J Gastroenterol 2001;96: 1143-1149. (C) 2001 by Am. Coll. o
f Gastroenterology).